Trial Profile
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sevirumab (Primary) ; Immune globulin
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Sandoz
- 21 Jul 2016 New trial record